Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Sanofi-Aventis S.A. ADR (SNY)

Sanofi-Aventis S.A. ADR (SNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 122,542,680
  • Shares Outstanding, K 2,529,783
  • Annual Sales, $ 50,266 M
  • Annual Income, $ 5,844 M
  • 60-Month Beta 0.60
  • Price/Sales 2.63
  • Price/Cash Flow 7.59
  • Price/Book 1.52
Trade SNY with:

Options Overview Details

View History
  • Implied Volatility 32.52% ( +8.94%)
  • Historical Volatility 20.90%
  • IV Percentile 95%
  • IV Rank 69.09%
  • IV High 39.81% on 04/24/24
  • IV Low 16.21% on 08/23/23
  • Put/Call Vol Ratio 4.26
  • Today's Volume 737
  • Volume Avg (30-Day) 570
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 37,300
  • Open Int (30-Day) 37,059

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.87
  • Number of Estimates 4
  • High Estimate 0.89
  • Low Estimate 0.85
  • Prior Year 0.95
  • Growth Rate Est. (year over year) -8.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.08 +0.96%
on 06/13/24
50.59 -6.05%
on 05/22/24
-2.68 (-5.34%)
since 05/13/24
3-Month
45.22 +5.11%
on 04/18/24
50.59 -6.05%
on 05/22/24
-0.71 (-1.47%)
since 03/13/24
52-Week
42.63 +11.49%
on 10/27/23
55.72 -14.70%
on 09/20/23
-2.99 (-5.92%)
since 06/13/23

Most Recent Stories

More News
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge

The integration of AI and healthcare is well underway.

LLY : 883.33 (+1.85%)
JNJ : 145.45 (+0.03%)
SNY : 47.53 (-1.88%)
Bull Market and Beyond: 3 Stocks Just Waiting to Soar

These pharma and biotech players could become long-term winners.

SNY : 47.53 (-1.88%)
NVAX : 15.05 (-5.11%)
PFE : 27.65 (-0.04%)
DNA : 0.4620 (-8.98%)
Why Vaccine Stocks Rallied This Week

A bird flu outbreak could spur demand for vaccines from these key players, but is it likely?

SNY : 47.53 (-1.88%)
MRNA : 145.23 (-1.69%)
NVAX : 15.05 (-5.11%)
BNTX : 96.00 (-1.95%)
PFE : 27.65 (-0.04%)
3 Things You Need to Know If You Buy Novavax Today

The vaccine maker's recovery story is looking brighter.

SNY : 47.53 (-1.88%)
PFE : 27.65 (-0.04%)
NVAX : 15.05 (-5.11%)
This Stock Just More Than Doubled in 1 Day: Is It a Buy?

The biotech still hasn't lost momentum.

NVAX : 15.05 (-5.11%)
SNY : 47.53 (-1.88%)
Could Novavax Become the Next Moderna?

Sanofi believes in Novavax's vaccine strengths...

SNY : 47.53 (-1.88%)
PFE : 27.65 (-0.04%)
NVAX : 15.05 (-5.11%)
MRNA : 145.23 (-1.69%)
2 Incredible Growth Stocks to Buy Hand Over Fist Right Now

These two healthcare stocks may be deeply undervalued.

ETN : 328.35 (+0.36%)
CPRX : 15.33 (-0.78%)
NVAX : 15.05 (-5.11%)
SNY : 47.53 (-1.88%)
Novavax Stock Just Tripled. Is It Too Late to Buy?

Novavax shares have soared and plummeted in recent years.

SNY : 47.53 (-1.88%)
NVAX : 15.05 (-5.11%)
Does Soaring Novavax Stock Have Enough Fuel to Climb Higher?

Moderate success regarding a new licensing deal with Sanofi could make the troubled vaccine stock a top performer.

PFE : 27.65 (-0.04%)
NVAX : 15.05 (-5.11%)
SNY : 47.53 (-1.88%)
Why Novavax Stock More Than Doubled Today

A cloud of doubt hanging over the company just gave way to some sunshine.

NVAX : 15.05 (-5.11%)
SNY : 47.53 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme,...

See More

Key Turning Points

3rd Resistance Point 48.25
2nd Resistance Point 47.92
1st Resistance Point 47.73
Last Price 47.53
1st Support Level 47.21
2nd Support Level 46.88
3rd Support Level 46.69

See More

52-Week High 55.72
Fibonacci 61.8% 50.72
Fibonacci 50% 49.18
Fibonacci 38.2% 47.63
Last Price 47.53
52-Week Low 42.63

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar